0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In vitro and in vivo anti-inflammatory and anticoagulant activities of Myrciaria plinioides D. Legrand ethanol leaf extract

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Myrciaria plinioides D. Legrand (Myrtaceae) is a native plant of Southern Brazil, which have potential in the food industry due to its edible fruits. Many plants belonging to this genus have been used for a variety of illnesses, including inflammatory disorders due to antioxidant properties. However, therapeutic uses of M. plinioides have been poorly studied. The aim of study was to assess the anti-inflammatory and anticoagulant activities of the ethanol leaf extract of M. plinioides. In M. plinioides extract-treated RAW 264.7 cells, assessments of cell viability, TNF-α release and p38 MAPK pathway-dependent protein expression were detected. In addition, rat paw edema models were used to analyze the anti-inflammatory effect of the extract. Macrophages cell line treated with M. plinioides extract showed a slight decrease in cell viability. In LPS-stimulated macrophages treated with different concentrations of the extract for 24 h, TNF-α release was inhibited, while modulation of p38 signaling pathway and inhibition of NF-κB p65 protein expression were dose-dependent. In rats, the extract inhibited the formation of paw edema, while an inhibitory effect on trypsin-like enzymes derived from mast cells was seen. Furthermore, the extract presented anticoagulant activity via extrinsic pathway, being able to block specifically factor Xa and thrombin. The study suggests that extract possess potent anti-inflammatory and anticoagulant effects. M. plinioides present great biological potential as a source for the development of anti-inflammatory and anticoagulant drugs. Additional studies can be proposed to better elucidate the mechanism by which M. plinioides exerts its effects.

          Related collections

          Most cited references50

          • Record: found
          • Abstract: found
          • Article: not found

          Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019

          This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Protective and pathogenic functions of macrophage subsets.

            Macrophages are strategically located throughout the body tissues, where they ingest and process foreign materials, dead cells and debris and recruit additional macrophages in response to inflammatory signals. They are highly heterogeneous cells that can rapidly change their function in response to local microenvironmental signals. In this Review, we discuss the four stages of orderly inflammation mediated by macrophages: recruitment to tissues; differentiation and activation in situ; conversion to suppressive cells; and restoration of tissue homeostasis. We also discuss the protective and pathogenic functions of the various macrophage subsets in antimicrobial defence, antitumour immune responses, metabolism and obesity, allergy and asthma, tumorigenesis, autoimmunity, atherosclerosis, fibrosis and wound healing. Finally, we briefly discuss the characterization of macrophage heterogeneity in humans.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Signaling in innate immunity and inflammation.

              Inflammation is triggered when innate immune cells detect infection or tissue injury. Surveillance mechanisms involve pattern recognition receptors (PRRs) on the cell surface and in the cytoplasm. Most PRRs respond to pathogen-associated molecular patterns (PAMPs) or host-derived damage-associated molecular patterns (DAMPs) by triggering activation of NF-κB, AP1, CREB, c/EBP, and IRF transcription factors. Induction of genes encoding enzymes, chemokines, cytokines, adhesion molecules, and regulators of the extracellular matrix promotes the recruitment and activation of leukocytes, which are critical for eliminating foreign particles and host debris. A subset of PRRs activates the protease caspase-1, which causes maturation of the cytokines IL1β and IL18. Cell adhesion molecules and chemokines facilitate leukocyte extravasation from the circulation to the affected site, the chemokines stimulating G-protein-coupled receptors (GPCRs). Binding initiates signals that regulate leukocyte motility and effector functions. Other triggers of inflammation include allergens, which form antibody complexes that stimulate Fc receptors on mast cells. Although the role of inflammation is to resolve infection and injury, increasing evidence indicates that chronic inflammation is a risk factor for cancer.
                Bookmark

                Author and article information

                Contributors
                marcia.goettert@univates.br
                Journal
                Inflammopharmacology
                Inflammopharmacology
                Inflammopharmacology
                Springer International Publishing (Cham )
                0925-4692
                1568-5608
                14 February 2022
                14 February 2022
                2022
                : 30
                : 2
                : 565-577
                Affiliations
                [1 ]GRID grid.441846.b, ISNI 0000 0000 9020 9633, Laboratório de Cultura de Células, , Programa de Pós-Graduação em Biotecnologia, Universidade do Vale do Taquari-Univates, ; Lajeado, Brazil
                [2 ]GRID grid.8395.7, ISNI 0000 0001 2160 0329, Departamento de Bioquímica e Biologia Molecular, , Universidade Federal do Ceará (UFC), ; Fortaleza, Brazil
                [3 ]GRID grid.414449.8, ISNI 0000 0001 0125 3761, Laboratório de Bioquímica Farmacológica, Centro de Pesquisa Experimental, , Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (CPE-HCPA/UFRGS), ; Porto Alegre, Brazil
                [4 ]GRID grid.8532.c, ISNI 0000 0001 2200 7498, Programa de Pós-Graduação em Biologia Celular e Molecular, Centro de Biotecnologia, , Universidade Federal do Rio Grande do Sul, ; Porto Alegre, Brazil
                [5 ]GRID grid.8532.c, ISNI 0000 0001 2200 7498, Faculdade de Farmácia, , Universidade Federal do Rio Grande do Sul, ; Porto Alegre, Brazil
                [6 ]GRID grid.10392.39, ISNI 0000 0001 2190 1447, Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, , University of Tübingen, ; Tübingen, Germany
                Author information
                http://orcid.org/0000-0002-3648-5033
                Article
                924
                10.1007/s10787-022-00924-0
                8948148
                35165808
                aec1823f-484b-44d1-90f4-dafd5e78a049
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 9 October 2021
                : 15 January 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100003810, Hospital de Clínicas de Porto Alegre;
                Funded by: FundRef http://dx.doi.org/10.13039/501100003593, Conselho Nacional de Desenvolvimento Científico e Tecnológico;
                Award ID: Edital MCTI/CNPq No. 14/2014
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100004263, Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul;
                Funded by: FundRef http://dx.doi.org/10.13039/501100002322, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior;
                Award ID: Finance Code 001
                Award Recipient :
                Funded by: Eberhard Karls Universität Tübingen (1020)
                Categories
                Original Article
                Custom metadata
                © Springer Nature Switzerland AG 2022

                Pharmacology & Pharmaceutical medicine
                myrciaria plinioides,anti-inflammatory activity,p38 signaling pathway,rat model,anticoagulant,extrinsic pathway

                Comments

                Comment on this article